Selected Grants
An Interventional Phase 3 Double Blind Randomized Study to Evaluate the Efficacy and Safety of PF-08634404 in Combination with Chemotherapy versus Bevacizumab in Combination with Chemotherapy in Treatment-Naive Participants with Metastatic Colorectal
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2031Optimizing Body Mass Index (BMI) with TCMCB07 in Patients with Newly Diagnosed Metastatic Colore
Clinical TrialPrincipal Investigator · Awarded by Endevica Bio · 2025 - 2030Effectiveness of T-DXd across HER2-positive solid tumors in patients who have received prior systemic treatment and have no satisfactory alternative treatment options: A hybrid observational study
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca UK Limited · 2025 - 2030A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2026 - 2029External Relationships
- Astra-Zeneca
- BurnaAI
- ShiftMedix
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.